Posts tagged CE Mark
VolitionRx reports positive interim Nu.Q diagnostic results in colorectal cancer

VolitionRx (NYSE American:VNRX) announced interim results from its first asymptomatic colorectal cancer (CRC) frontline screening study in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark, with 680 subjects from the Danish National CRC Screening Program.

Read More
RepliCel dermal injection device gets U.S. patent

RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has received a key patent in the U.S. covering significant components of its novel, multi-needle dermal injection device. 

Read More
Profound Medical sells first TULSA-PRO in Finland

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has successfully completed the first sale of a TULSA-PRO system in Finland to the Turku University Hospital, in collaboration with Royal Philips, who is working in partnership with Profound to commercialize the TULSA-PRO system in Europe.

Read More
Echelon starts Profound Medical at buy

Echelon Wealth Partners initiated coverage of Profound Medical (OTCQX:PRFMF; TSXV:PRN) with a “buy” rating and one-year price target of $4. The stock closed at 78 cents on March 14.

Read More
RepliCel in service partnerships for dermal injector

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP; FRA:P6P2) has signed agreements with two European firms to get the company's commercial-grade RCI-02 dermal injector prototypes manufactured and tested.

Read More
Roth starts Arch Therapeutics at buy

Roth Capital Partners initiated coverage of Arch Therapeutics (OTC:ARTH) with a ‘buy” rating and $3 price target. The stock closed at 66 cents on Feb. 13.

Read More
RepliCel receives two patents in Europe

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP) announced the granting of two patents in Europe related to its multi-needle dermal injection technologies. 

Read More
Canaccord ups GenMark price target to $10.50

Canaccord Genuity has hiked its price target for GenMark Diagnostics (NASDAQ:GNMK) to $10.50 from $8. The stock closed at $9.27 on Wednesday.

After the close yesterday, GNMK announced a major milestone, achieving CE Mark for both its ePlex instrument and ePlex Respiratory Pathogen Panel, which was three weeks ahead of its recent timeline by the end of June.

Read More